Showing 1–8 of 8 · Genomics & precision medicine
FY2025 revenue $642.8m (+5.2%); operating margin -9.5%; net loss $43.5m.
Revenue includes $44.1m patent settlement; underlying revenue fell 2%. No debt.
Listed (300676.SZ).
Latest full-year results not yet captured by HSH.
Parent Roche (ROG.SW) group FY2025 revenue CHF 61.52bn (+2.0%); core operating margin 35.5%; net income CHF 13.80bn.
Diagnostics division sales CHF 13.85bn (+2% at constant exchange rates).
FY2025 revenue $4.34bn (-0.7%); operating margin 18.6%; net income $850.0m.
Cash $1.63bn; debt $1.99bn.
FY2025 revenue £223.9m (+22.2%); operating margin -69.4%; net loss £145.2m.
No debt; £302.8m cash.
FY2025 revenue $2.09bn (+6.0%); adjusted operating margin 29.5%.
Net sales rounded in release; diluted EPS $1.94. Full GAAP figures in annual report.
FY2025 revenue $77.3m (+19.0%); operating margin -91.7%; net loss $79.0m.
Balance sheet figures not captured from release.
FY2025 revenue $1.27bn (+83.4%); operating margin -19.9%; net loss $245.0m.
Cash $759.7m; debt $1.24bn.